» Articles » PMID: 12654924

Determinants of Inhibition of Transiently Expressed Voltage-gated Calcium Channels by Omega-conotoxins GVIA and MVIIA

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Mar 26
PMID 12654924
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The Conus magus peptide toxin omega-conotoxin MVIIA is considered an irreversible, specific blocker of N-type calcium channels, and is now in clinical trials as an intrathecal analgesic. Here, we have examined the action of MVIIA on mutant and wild type calcium channels transiently expressed in tsA-201 cells. Although we have shown previously that mutations in a putative external EF-hand motif in the domain IIIS5-H5 region alters block by both omega-conotoxin GVIA and MVIIA (Feng, Z. P., Hamid, J., Doering, C., Bosey, G. M., Snutch, T. P., and Zamponi, G. W. (2001) J. Biol. Chem. 276, 15728-15735), the introduction of five point mutations known to affect GVIA blocking (and located downstream of the EF-hand) affected MVIIA block to a smaller degree compared with GVIA. These data suggest that despite some overlap, MVIIA and GVIA block does not share identical channel structural determinants. At higher concentrations (approximately 3 microm), MVIIA reversibly blocked L-, P/Q-, and R-type, but not T-type channels, indicating that the overall architecture of the MVIIA site is conserved in all types of high voltage-activated calcium channels. A kinetic analysis of the MVIIA effects on the N-type channel showed that MVIIA blocked resting, open, and inactivated channels. Although the development of MVIIA block did not appear to be voltage-, nor frequency-dependent, the degree of recovery from block strongly depended on the potential applied during washout. Interestingly, the degree of washout was highly variable and appeared to weakly depend on the holding potential applied during toxin application. We propose a model in which N-type calcium channels can form both reversible and irreversible complexes with MVIIA.

Citing Articles

C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models.

Tang C, Gomez K, Chen Y, Allen H, Hestehave S, Rodriguez-Palma E J Clin Invest. 2024; 135(4).

PMID: 39656529 PMC: 11827853. DOI: 10.1172/JCI177429.


Peptide and Peptidomimetic Inhibitors Targeting the Interaction of Collapsin Response Mediator Protein 2 with the N-Type Calcium Channel for Pain Relief.

Perez-Miller S, Gomez K, Khanna R ACS Pharmacol Transl Sci. 2024; 7(7):1916-1936.

PMID: 39022365 PMC: 11249630. DOI: 10.1021/acsptsci.4c00181.


A comprehensive review on ziconotide.

Lin J, Chen S, Butt U, Yan M, Wu B Heliyon. 2024; 10(10):e31105.

PMID: 38779019 PMC: 11110537. DOI: 10.1016/j.heliyon.2024.e31105.


MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy.

Harman T, Udoh M, McElroy D, Anderson L, Kevin R, Banister S Front Physiol. 2023; 14:1086243.

PMID: 37082241 PMC: 10110893. DOI: 10.3389/fphys.2023.1086243.


The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels.

Udoh M, Bladen C, Heblinski M, Luo J, Janve V, Anderson L Front Pharmacol. 2022; 13:1048259.

PMID: 36386164 PMC: 9664070. DOI: 10.3389/fphar.2022.1048259.